

Company Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing innovative therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Rexahn and Ocuphire Enter into Definitive Merger Agreement

Jun 17 2020, 11:30 PM EDT

Rexahn to Explore Strategic Alternatives

Sep 24 2019, 6:50 AM EDT

Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development

Aug 7 2019, 6:30 AM EDT

Stock Overview

Symbol	REXN
Exchange	Nasdaq
Market Cap	9.82m
Last Price	\$2.19
52-Week	\$1.2626 - \$4.26

10/20/2020 03:59 PM EDT

Investor Relations

ir@rexahn.com

Management Team

Douglas J. Swirsky

President and Chief Executive Officer

DJ Kim, Ph.D.

Vice President and Head of Research and Development

Rexahn Pharmaceuticals, Inc.

15245 Shady Grove Road
Suite 455
Rockville, MD 20850

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.